Your browser doesn't support javascript.
loading
The burden of the coronavirus disease 2019 virus infection in Burkina Faso: Results from a World Health Organization UNITY population-based, age-stratified sero-epidemiological investigation.
Ouedraogo, Samiratou; Traoré, Isidore Tiandiogo; Kania, Dramane; Kaboré, Nongodo Firmin; Mamguem Kamga, Ariane; Badolo, Hermann; Yara, Mimbouré; Sanou, Guillaume; Koné, Amariane; Kagoné, Samdapawindé Thérèse; Ouédraogo, Esperance; Konaté, Blahima; Médah, Rachel; de Rekeneire, Nathalie; Poda, Armel; Diendere, Arnaud Eric; Ouédraogo, Boukary; Billa, Oumar; Paradis, Gilles; Tinto, Halidou; Dabakuyo-Yonli, Tienhan Sandrine.
Afiliación
  • Ouedraogo S; Observatoire national de la santé de la population (ONSP) Institut National de Santé Publique (INSP) Ouagadougou Burkina Faso.
  • Traoré IT; Institut National de Santé Publique du Québec (INSPQ) Montreal Quebec Canada.
  • Kania D; The Department of Epidemiology, Biostatistics and Occupational Health, Faculty of Medicine McGill University Montreal Quebec Canada.
  • Kaboré NF; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso Burkina Faso.
  • Mamguem Kamga A; Institut Supérieur des Sciences de la Santé (INSSA) Université Nazi Boni Bobo-Dioulasso Burkina Faso.
  • Badolo H; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso Burkina Faso.
  • Yara M; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso Burkina Faso.
  • Sanou G; Epidemiology and Quality of Life Research Unit, INSERM U1231 Georges Francois Leclerc Centre-UNICANCER Dijon France.
  • Koné A; Observatoire national de la santé de la population (ONSP) Institut National de Santé Publique (INSP) Ouagadougou Burkina Faso.
  • Kagoné ST; Observatoire national de la santé de la population (ONSP) Institut National de Santé Publique (INSP) Ouagadougou Burkina Faso.
  • Ouédraogo E; Centre National de Recherche et de Formation sur le Paludisme Institut National de Santé Publique Ouagadougou Burkina Faso.
  • Konaté B; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso Burkina Faso.
  • Médah R; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso Burkina Faso.
  • de Rekeneire N; Département de médicine, pharmacopée traditionnelle et pharmacie Institut de Recherche en Sciences de la Santé (IRSS)-Centre National de la Recherche Scientifique et Technologique (CNRST) Ouagadougou Burkina Faso.
  • Poda A; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso Burkina Faso.
  • Diendere AE; Institut des Sciences des Sociétés (INSS)-Centre National de la Recherche Scientifique et Technologique (CNRST) Ouagadougou Burkina Faso.
  • Ouédraogo B; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso Burkina Faso.
  • Billa O; Centre MURAZ, Institut National de Santé Publique Bobo-Dioulasso Burkina Faso.
  • Paradis G; Expertise France Paris France.
  • Tinto H; Institut Supérieur des Sciences de la Santé (INSSA) Université Nazi Boni Bobo-Dioulasso Burkina Faso.
  • Dabakuyo-Yonli TS; Service des maladies infectieuses Centre Hospitalier Universitaire Sourô Sanou Bobo-Dioulasso Burkina Faso.
Influenza Other Respir Viruses ; 17(11): e13216, 2023 Nov.
Article en En | MEDLINE | ID: mdl-38019697
BACKGROUND: This study aimed to estimate the anti-SARS-CoV-2 antibody seroprevalence in the general population of Bobo-Dioulasso and Ouagadougou (Burkina Faso). METHODS: We collected from March to April 2021 blood samples from randomly selected residents in both main cities based on the World Health Organization (WHO) sero-epidemiological investigations protocols and tested them with WANTAI SARS-CoV-2 total antibodies enzyme-linked immunosorbent assay (ELISA) kits intended for qualitative assessment. We also recorded participants' socio-demographic and clinical characteristics and information on exposure to SARS-CoV-2. Data were analysed with descriptive and comparative statistics. RESULTS: We tested 5240 blood samples collected between 03 March and 16 April 2021. The overall test-adjusted seroprevalence for SARS-CoV-2 antibodies was (67.8% [95% CI 65.9-70.2]) (N = 3553/3982). Seroprevalence was highest among participants aged 15-18 years old (74.2% [95% CI 70.5-77.5]) (N = 465/627), compared with those aged 10-14 years old (62.6% [95% CI 58.7-66.4]) (N = 395/631), or those over 18 (67.6% [95% CI 66.2-69.1]) (N = 2693/3982). Approximately 71.0% (601/860) of participants aged 10-18 years old who tested positive for SARS-CoV-2 antibodies experienced no clinical COVID-19 symptoms in the weeks before the survey, compared with 39.3% (1059/2693) among those aged over 18 years old. CONCLUSION: This study reports the results of the first known large serological survey in the general population of Burkina Faso. It shows high circulation of SARS-CoV-2 in the two cities and a high proportion of asymptomatic adolescents. Further studies are needed to identify the SARS-CoV-2 variants and to elucidate the factors protecting some infected individuals from developing clinical COVID-19.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Adolescent / Adult / Child / Humans / Middle aged País/Región como asunto: Africa Idioma: En Revista: Influenza Other Respir Viruses Asunto de la revista: VIROLOGIA Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Adolescent / Adult / Child / Humans / Middle aged País/Región como asunto: Africa Idioma: En Revista: Influenza Other Respir Viruses Asunto de la revista: VIROLOGIA Año: 2023 Tipo del documento: Article Pais de publicación: Reino Unido